Data Show Underutilization of Appendectomy in Appendix Cancer Population

News
Video

A lack of guidelines, a loss of follow-up, and out-of-state procedures are all potential reasons for 26% of patients undergoing appendectomy.

Muhammad Talha Waheed, MD, coauthored a study that ultimately found that only a little more than a quarter—26%—of patients with appendiceal cancer received appendectomy alone.


Waheed, a postdoctoral research fellow at City of Hope Comprehensive Cancer Center in Duarte, California, believes this is a “concern” because there are guidelines that do recommend a right hemicolectomy for appendiceal carcinomas. While conducting the study, investigators hypothesized this gap may have been due to subgroups of patients with greater comorbidities. They ultimately found that was not the case and that there was an “underutilization” of appendectomy, particularly at Commission on Cancer–accredited hospitals.

CancerNetwork® spoke with Waheed before the 2025 Society of Surgical Oncology Annual Meeting about a poster he presented on the differences in outcomes between the 2 approaches in patients with appendiceal cancer.

He gave potential reasons why this number for appendectomy use was low, such as a loss of follow-up, out-of-state procedures, or the lack of guidelines, but emphasized that “we should advocate for these patients to get a definite resection if needed.”

Transcript:

[The underutilization of right colectomy] is a key finding of the paper. This does not take away from the results because the main question of our paper remains, “When patients get a right colectomy, what is the optimal sequence of the resection?”

This underutilization of right colectomy after appendectomy is a key finding. It’s a cause of concern because although some large databases do support appendectomy alone in certain clinical scenarios for appendiceal adenocarcinomas—for example, in the setting of appendiceal adenocarcinomas or well-differentiated mucinous appendiceal carcinomas— the Chicago Consensus Guidelines or the American Society of Colon and Rectal Surgeons guidelines do recommend a right hemicolectomy for appendiceal adenocarcinomas. That [prompted] us to ask if there is a risk vs benefit question that is going on. Do these patients have more comorbidities or sickness? Is that why these patients did not undergo colectomy? When we looked at it, [more] patients underwent appendectomy alone and had no or minimal reported comorbidities. This underutilization remained very high in patients treated at [Commission on Cancer–accredited] hospitals.

We speculate that this could be because of lack of consensus guidelines for appendiceal adenocarcinomas up until recently. It could be because of a loss of follow-up, or maybe these patients were traveling out of state, got their first resection, and went back, traveled, and got their resection out of state. We were not able to capture that. Regardless, this should be explored further. We should advocate for these patients to get a definite resection if needed.

Reference

Waheed MT, Malik I, Ituarte PHG, et al. Upfront colectomy vs. initial appendectomy followed by completion colectomy for appendiceal cancer: comparison of outcomes. Presented at: 2025 Society of Surgical Oncology Annual Meeting; March 27-29, 2025; Tampa, FL.

Recent Videos
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content